The renin–angiotensin system : a possible new target for depression

REVIEW Open Access The renin–angiotensin system: a possible new target for depression João Vian 1,2† , Círia Pereira 1,2† , Victor Chavarria 3† , Cristiano Köhler 4 , Brendon Stubbs 5,6,7,8 , João Quevedo 9,10,11,12 , Sung-Wan Kim 15 , André F. Carvalho 4 , Michael Berk 13,14 and Brisa S. Fernandes 13* Abstract Depression remains a debilitating condition with an uncertain aetiology. Recently, attention has been given to the renin–angiotensin system. In the central nervous system, angiotensin II may be important in multiple pathways related to neurodevelopment and regulation of the stress response. Studies of drugs targeting the renin–angiotensin system have yielded promising results. Here, we review the potential beneficial effects of angiotensin blockers in depression and their mechanisms of action. Drugs blocking the angiotensin system have efficacy in several animal models of depression. While no randomised clinical trials were found, case reports and observational studies showed that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers had positive effects on depression, whereas other antihypertensive agents did not. Drugs targeting the renin–angiotensin system act on inflammatory pathways implicated in depression. Both preclinical and clinical data suggest that these drugs possess antidepressant properties. In light of these results, angiotensin system-blocking agents offer new horizons in mood disorder treatment. Keywords: Depression, Psychiatry, Inflammation, Renin–angiotensin system, Angiotensin, ATR1, ATR2, Mas, Angiotensin receptor blockers, Angiotensin-converting enzyme inhibitors Background The pathophysiology of depression remains elusive and current treatments, which focus on traditional pathways (monoamine alterations), are only partially effective. Remission rates in the treatment of depression are only about 30% for those treated with traditional pharmacotherapy, and multiple agents are often required to achieve an adequate level of recovery [1] Evidence points to the involvement of neuroinflammation, oxidative and nitrosative stress pathways, mitochondrial dysfunction and neurotrophic signalling in depression [2]. Recently, the renin–angiotensin system (RAS) was proposed to be implicated in depression, and that blocking this system, either with angiotensin-converting enzyme inhibitors (ACEIs) or with angiotensin II type 1 receptor (AT1R) blockers, would translate into clinical benefits for the depression treatment [3–7]. Here, we review the literature so far on RAS-targeting drugs in depression. Methods A PubMed search was conducted for literature published between January 1974 and June 2017. Search terms included were: depression OR inflammation OR anxiety OR mood AND renin–angiotensin system, angiotensin, ATR1, ATR2, angiotensin receptor blockers, angiotensinconverting enzyme inhibitors, ATR3, ATR4, Mas, and aldosterone. Systematic reviews, randomised controlled trials (RCTs), observational studies, case series and animal studieswithanemphasisontheangiotensinsystemanditsrole in depression were included. Articles not in English were excluded. The PubMed search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review. The RAS in the brain The RAS was discovered in the 19 th Century, after the blood pressure-raising agent renin was first identified in the rabbit kidney [8]. In time, the RAS became an established and extensively studied peripheral regulator of blood pressure and renal-mediated body fluid homeostasis, and was discovered to be a central target in clinical hypertension therapy. Renin, a protein synthesised by the * Correspondence: [email protected] † Equal contributors 13 Deakin University, IMPACT Strategic Research Centre, School of Medicine, University Hospital Geelong, Barwon Health, Geelong, VIC, Australia Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Vian et al. BMC Medicine (2017) 15:144 DOI 10.1186/s12916-017-0916-3 juxtaglomerular cells of the kidney, cleaves the polypeptide angiotensinogen to generate angiotensin I (Ang I). This peptide is metabolised to angiotensin II (Ang II) by angiotensin I-converting enzyme (ACE). It was surprising when renin was identified in the dog brain in 1971 [9, 10]. Subsequently, intracranial Ang II was shown to elevate blood pressure and to promote fluid intake [11–14], suggesting that angiotensin receptors were present in the brain. The actions of Ang II in the central nervous system are mediated mainly by two receptor types: AT1R and AT2R [15, 16]. Other receptors, including MAS [17], the (pro)renin receptor (PRR) [18] and AT4R [19], have also recently been identified but their roles remain less well characterised. AT3R was first reported as a new binding site for Ang II in mouse neuroblastoma cell cultures [20], but a separate gene for this receptor remains to be sequenced in humans. AT1R mediates most of the peripheral and central actions of Ang II [21] and is implicated in multiple pathways related to regulation of the stress response. Stimulating AT1R contributes to the release of inflammatory markers [22]. Ang II interacts with AT1Rs, activating the NADPH–oxidase complex [23–25], the microglial RhoA/Rho kinase pathway [26–28], NF-kappa B, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). In turn, activated COX-2 forms an intermediate in several key aspects of central nervous system inflammation, and in oxidative and nitrosative stress (see Fig. 1). AT1R stimulation also releases tumour necrosis factor α(TNF-α) [29, 30], which is important in several neurodegenerative disorders [29, 31–33], and regulates activation of the hypothalamic–pituitary–adrenal axis. Stimulation of AT1R in the parvocellular hypothalamic paraventricular nucleus (PVN) by Ang II increases production of corticotrophin-releasing factor [34–36]. In turn, this spurs adrenocorticotropic hormone secretion in the anterior pituitary gland, starting the stress response cascade. Accordingly, in humans, AT1R blockade downregulates hypothalamic–pituitary–adrenal axis activation [37]. Ang II also stimulates the release of aldosterone via AT1R in the adrenal cortex of the kidney [38]. Thus, the acronym ‘RAAS’(as in renin–angiotensin–aldosterone system) is often used. Besides being regulated by Ang II, aldosterone release is also stimulated by adrenocorticotropic hormone and the sympathetic nervous system. The role of aldosterone in the brain has previously been downplayed because its specific intracellular receptor, the mineralocorticoid receptor (MR), shares affinity with cortisol, which circulates at a ~1000-fold higher concentration than aldosterone [39]. For a tissue to be sensitive to aldosterone, it must express 11β-hydroxysteroid dehydrogenase type 2 (HSD-2) protein, which degrades cortisol, freeing the MR to the action of aldosterone. HSD-2 has been identified in the brain, mainly in the nucleus of the solitary tract, but also in the PVN [40]; regions that also express AT1R. Surprisingly –paralleling the history of angiotensin –aldosterone synthesis was also recognised in the amygdala, hippocampus and hypothalamus of the brain [41]. AT1R is particularly dense in the anterior pituitary; the circumventricular organs (area postrema; subfornical organ, the vascular organ of lamina terminalis and the Fig. 1 Pathways involved in neuronal damage of angiotensin II through AT1 receptor agonism. Ang II, angiotensin II; AT1R, angiotensin II receptor type 1; PGE2, prostaglandin E2; Cox-2, Cyclooxygenase-2; PPAR-γ, peroxisome proliferator-activated receptor gamma; NF-kB, nuclear factor kappa-lightchain-enhancer of activated B cells; iNOS, inducible nitric oxide synthase; NO, nitric oxide; ROS, reactive oxygen species Vian et al. BMC Medicine (2017) 15:144 Page 2 of 13 median eminence); the lateral geniculate body; inferior olivary nucleus; the nucleus of the solitary tract and in the PVN, the preoptic and the supraoptic nuclei of the hypothalamus [42]. Modern molecular approaches have revealed that AT2R is also expressed in the adult brain [43, 44]. AT2R is involved in neurodevelopment [45–49] and participates in cell growth inhibition, fetal tissue development, extracellular matrix modulation, neuronal regeneration, apoptosis, cellular differentiation, and, possibly, vasodilation and left ventricular hypertrophy [50]. AT2R stimulation exerts neuroprotective effects in ischaemic stroke in rodents [51–55], and while the underlying mechanism remains to be fully characterised, it seems to partly involve an increase in the anti-inflammatory cytokine interleukin-10 [56]. AT2R is particularly dense in the amygdala, caudate putamen, medial geniculate body, globus pallidus, habenula, hypoglossal nucleus, inferior colliculus, inferior olivary nucleus, locus coeruleus, thalamus, and ventral tegmental area [42]. More components of the RAS such as ACE2, angiotensin-(1–7) and the Mas receptor have recently been identified in the brain. This alternative pathway is sometimes referred to as the non-classical RAS [57]. Originally identified in 1986 as an oncogene in mice [58], the tumorigenic power of Mas was later discredited and remained an orphan receptor until it was subsequently shown to bind with Ang (1–7) [17]. ACE2 can hydrolyse Ang II to produce Ang-(1–7). It can also cleave Ang I, producing Ang- (1–9) with subsequent Ang-(1-7) formation, although with much less efficiency. Mas is thus proposed to be a receptor for Ang-(1-7), with its highest expression in the brain [59]. The action of Ang-(1–7) through Mas is thought to influence arachidonic acid production and nitric oxide synthase activation [60] (see Fig. 2). The recently discovered PRR is highly expressed in the brain [18]. Its large extracellular domain binds and captures renin and its almost inactive precursor prorenin, increasing their enzymatic activities [61], but it also mimics the actions of AT1R through intracellular signalling [62]. A specific receptor for angiotensin IV (Ang IV), another less active peptide than Ang II, was first identified in a guinea pig hippocampus [19]. It is thought that the identity of AT4R was established when it was discovered that Ang IV is a strong inhibitor of insulin-regulated aminopeptidase (IRAP) [63]. IRAP is responsible for oxytocin degradation and, as demonstrated when an injection of Ang IV abolished the antidepressant effects of oxytocin in mice [64], is apparently required for its mood effects to take place. Yet recently, discrepancies between Ang IV binding site-antagonist and IRAP inhibitors [60], or the unaltered cognitive response of Ang IV in IRAP knockout mice [65], have cast doubt on whether IRAP is the only AT4R receptor. Further candidates for the role of AT4R have been proposed [42]. Ang II is also involved in cerebral blood flow regulation [21, 22]. Rising circulating Ang II is free to cross into the subfornical organ. This is a circumventricular organ lacking the blood–brain barrier, which, via AT1R, signals the paraventricular nucleus of the hypothalamus to activate the rostral ventrolateral medullary neurons and peripheral sympathetic nerves, thereby raising blood pressure [66]. Overstimulation of AT1Rs can lead to endothelial dysfunction [67] and neuronal injury and vulnerability caused by cerebrovascular remodelling [68–72]. It is well established that angiotensin receptors are present in the brain, yet the origin of active angiotensin peptides in the brain remains somewhat controversial. Researchers are puzzled because while Ang II is too hydrophilic to cross the blood–brain barrier [73], expression of Fig. 2 Pathway from angiotensinogen to AT1, AT2 and Mas receptors. ACE, Angiotensin-converting enzyme Vian et al. BMC Medicine (2017) 15:144 Page 3 of 13 renin in the brain is too low to account for its local synthesis [74]. Among the hypotheses advanced to solve this apparent paradox are renin-independent synthesis of angiotensin peptides [75]; impaired blood–brain barrier in hypertension leading to Ang II leaking into the cerebrospinal fluid [73]; an intracellular form of renin in the brain [76] or undetectable renin caused by its sequestration by PRR [62]. Although uncertainties persist, targeting the brain RAS or the peripheral RAS cannot be equal because ACEIs that penetrate the blood–brain barrier are superior to non-centrally acting ones in preventing cognitive decline [77, 78]. Major depressive disorder (MDD) and neuroinflammation: pre-clinical data Inflammation is essential for restoring homeostasis in stress, infection and injury [79]. Hormones and circulating pro-inflammatory cytokines, products of neuronal injury and bacterial endotoxins, activate transcription factors. Activated inflammatory cascades with brain parenchymal microglia and blood-derived infiltrating macrophages also participate [80]. A well-regulated central inflammatory chain is fundamental to restore homeostasis, but an exaggerated response can be responsible for chronic inflammation, neuronal damage and a decrease in brain-derived neurotrophic factor [81–86]. Thus, excess or sustained activation of immune responses augments the risk of disease in vulnerable individuals, and can be important in the pathophysiology of many neurological and psychiatric disorders [2, 81, 87–96]. The inflammatory hypothesis [97, 98] postulates that depression is the result of altered immune-inflammatory pathways. This leads to increased immune activation, inflammation, nitro-oxidative stress and alteration of the kynurenine pathway, which ultimately causes changes in monoamine levels. MDD is characterised by a low-grade inflammatory state with increased peripheral levels of inflammatory cytokines, and microglial activation [98–103]. Normalised levels of inflammatory markers are associated with remission of clinical depression [104], while persistently elevated levels are associated with a lack of response to antidepressants [105]. Elevated levels of inflammatory markers such as C-reactive protein (CRP) may increase the risk of a first episode of depression [106, 107]. However, a large Mendelian randomisation study found no causal association between increased CRP levels and depression in people with genetically elevated CRP [108], and also that inflammation may better stratify those who will or will not benefit from antiinflammatory treatments [109]. More compelling is the strong observation of depressive symptoms induced by interferon-αtreatment, both in humans and in animal models [110–113]. Consequently, it has been hypothesised that drugs with anti-inflammatory properties might also demonstrate antidepressant potential. Nonsteroidal anti-inflammatory drugs have shown benefits [114, 115], although no influence was observed in association with antidepressants [116]. Cytokine inhibitors were found to improve depression [117–119] and specific depressive symptoms, such as anxiety [120] and fatigue [117], among patients with psoriasis [117, 118, 120] or ankylosing spondylitis [119]. This finding is supported by evidence from animal models [121]. In an open-label report, aspirin exhibited antidepressive effects, even at low doses [122], and may have a more favourable benefit/risk ratio compared with selective COX-2 inhibitors [123, 124]. Epidemiological reports also support antidepressant effects of aspirin [106, 125]. N-acetylcysteine may also be useful in treating MDD [126–128]. Statins, which apart from their antiatherosclerotic and cardioprotective effects also display neuroprotective and anti-inflammatory effects [129–131], showed the potential to produce moodrelated benefits [132] and are associated with a reduced risk of depression [133]. Clinical trials of statins seem to show antidepressant effects in aggregate [134]. In a meta-analysis, supplementing the treatment of severe MDD with polyunsaturated fatty acids (PUFAs) was found to be beneficial, even though its role in mild-tomoderate depression or prevention seems limited [135]. Studies attempting to link depression with genetic variations in the RAS provide additional evidence. Initial reports for the most studied ACE polymorphism (I/D) –the presence or absence of a 287-bp fragment in intron 16 related to ACE serum levels [136] –were inconsistent and a metaanalysis showed no significance [137, 138]. However, other single nucleotide polymorphisms have been associated with depression [139, 140], including the GG genotype of ACE A2350G, which also correlated with higher ACE serum activity [141]. Recently, seven single nucleotide polymorphisms were significantly tied to late-life depression and cortisol levels under stressful circumstances [142]. The AT1R genotype (A1166C) CC is also associated with depression and increased responsiveness to Ang II [6], as well as clinical response [143, 144]. Epigenetic mechanisms also appear to be important, as altered methylation of the regulatory region of the ACE gene has been associated with depression [145]. ACE polymorphisms even seem able to influence antidepressant response [145–147], cognitive function after a depression episode in the elderly [148, 149], or suicide behaviour [150, 151]. The role of aldosterone in depression is an emerging area of research, thus regulation of aldosterone by the RAS is another point to take into account. Patients with primary hyperaldosteronism have depressive symptoms [152, 153]. In animal models, administering aldosterone leads to depressive behaviour [154], anxiety [155] and Vian et al. BMC Medicine (2017) 15:144 Page 4 of 13 anhedonia [156]. Eplerone, an aldosterone antagonist, had anxiolytic properties in rats [157]. Poorer clinical outcome in MDD is predicted by higher salivary aldosterone [158, 159]. Conversely, MDD patients with suicidal behaviour had lower concentrations of aldosterone compared to suicidal patients without MDD and non-suicidal depressive patients [160]. Spironolactone, another MR antagonist, induces a sleep pattern characteristic of melancholic depression and reduces the efficacy of amitriptyline [40]. This hints at a nonlinear dynamic of aldosterone throughout the MDD episode, prompting its exploration as a biomarker that is able to differentiate depression duration. Indeed, at least in women, higher aldosterone levels are associated with a shorter duration of a depressive episode [159], and in an animal model were used to mark the onset of depression [161]. Taking the above evidence in aggregate, current understanding of the pathophysiology of depression supports the search for novel therapeutics affecting the pathways of inflammation, oxidative biology, apoptosis and neurogenesis. Besides their anti-inflammatory effects, angiotensin receptor blockers (ARBs) and ACEIs have good tolerability, limited side effects and are already widely used drugs approved by the US Food and Drug Administration [162, 163]. Their neuroprotective, antiinflammatory, vasodilatory [164] and microglia activation inhibitory effects [29] make them candidates for novel therapeutic targets for inflammatory brain diseases and cognitive disorders [21, 29, 30, 165, 166]. In this regard, interesting data is emerging from animal models. The body of evidence supporting the antidepressant and antianxiety effects of drugs targeting the RAS in animal models is increasing. Mutant mice lacking the angiotensin gene have less depressive-like behaviour in the forced swim test [167]. Pharmacologically decreasing the production of Ang II by administering captopril (an ACEI) produces an analogous result [168]. Blockage of Ang II also leads to antidepressant-like activity in the learned helplessness [169] and chronic mild stress paradigms [170, 171], both more valid models than the forced swim test. Preclinical data also suggests a link between the antidepressant effect and a decrease in Ang II activity; AT1R antagonism by its specific blockers losartan [3], valsartan [171], irbesartan [170] and telmisartan [172] has similar actions to that caused by ACEIs. As with most antidepressants, use of these blockers also seems to have antianxiety properties. Candesartan [21, 173], losartan [174, 175] and captopril [176] reduced anxiety behaviour (promoting exploration) in the elevated plus maze test. Nevertheless, enalapril (a non-centrally acting ACEI) was not effective in normotensive rats [175]. Remarkably, different phenotypes of anxiolytic response to ARBs across different mice strains may be explained by differences in AT1R expression levels [177]. Curiously, mood effects were also apparent in an amphetamineinduced model of mania in mice, which candesartan was able to prevent and treat with comparable efficacy to lithium [30]. Transgenic rats overexpressing Ang-(1-7) [178] or ACE2 [179] showed a reduced anxiety phenotype that is seemingly dependent on Mas signalling, since antagonism of Mas reversed the phenotype. Administering Ang- (1-7) was associated with decreased oxidative stress markers in the amygdala [180]. The same Mas antagonism also prevented the anxiolytic/antidepressant effect of enalapril in transgenic hypertensive rats [181, 182]. These agents seem to influence mood disorders independently of their blood pressure-lowering activity. A study exploring the effect of valsartan in a chronic mild stress model found no change in average blood pressure after a month of treatment, while at the same time registering antianxiety and antidepressant effects [171]. Animal experiments also support the anti-inflammatory and oxidative stress-reducing effects of these drugs as part of their mechanisms of action. Both irbesartan and fluoxetine decreased levels of thiobarbituric-reactive substances –oxidative stress markers –while increasing catalase and glutathione (antioxidants) and serotonin (5-HT) levels in the brain [170]. Valsartan also increased neurogenesis in mice [171]. Captopril and perindopril (both centrally acting ACEIs) [183], telmisartan [183, 184] and candesartan [21, 185, 186] all show anti-inflammatory effects by reducing microglial activation and levels of inflammatory markers such as nitric oxide and TNF-α. Clinical data To date, no RCT has assessed the effects of ACEIs or ARBs in depression. However, observational studies have established a bidirectional link between cardiovascular disorders and depression. Antihypertensive sympatholytic drugs such as reserpine or clonidine can induce depression [187–189], prompting some to propose that sympathetic nervous system hyperreactivity is a common substrate [190, 191]. It was unclear whether this association was caused by hypertension itself, its treatment, or both [192, 193]. A meta-analysis of prospective cohort studies [194] found no evidence that hypertension is a risk factor for depression. However, the contrary –that depression increases the risk of developing hypertension –has been suggested [195] and confirmed by a meta-analysis [196]. In light of all the evidence, the RAS now emerges as a major link between mood and the cardiovascular system. In the early 1980s, several cases reported that captopril might promote mood elevation in patients with MDD [197–199]. Mood benefits were reported in 9 patients Vian et al. BMC Medicine (2017) 15:144 Page 5 of 13 with MDD, and one with bipolar disorder, who were treated with lisinopril (an ACEI) [200]. In each case, patients were being treated for hypertension or cardiac heart failure (see Table 1). In a case-control study of 972 patients from primary care practices, who had both diabetes and a new diagnosis of depression, those exposed to ACEIs in the last 6 months showed a lower odds ratio for depression (OR 1.3, 95% CI: 0.8–2.2) compared to those exposed to beta-blockers (BBs) (OR 2.6, 95% CI: 1.1–7.0) and calcium channel blockers (CCBs) (OR 2.2, 95% CI: 1.2–4.2) [201]. In a recent population cohort study, ACEIs decreased the incidence of MDD [202]. These results were replicated by Boal et al. [203], who examined moodrelated hospital admissions of 144,660 patients treated with antihypertensive monotherapy for a five-year follow-up. Interestingly, ACEIs and ARBs were associated with the lowest risk of mood disorder admissions (log-rank P= 0.006), while CCBs (hazard ratio (HR) = 2.28, [95% CI 1.13–4.58]; P= 0.02) and BBs (HR = 2.11, [95% CI 1.12 –3.98]; P= 0.02) were associated with increased risk compared to ACEIs and ARBs. There was no significant difference in patients receiving no antihypertensive medication (HR = 1.63 [95% CI 0.94–2.82]; P = 0.08), or those taking thiazide diuretics (HR = 1.56 [95% CI 0.65–3.73]; P= 0.32). However, in the CREATE trial, a randomised placebocontrolled trial of citalopram in 284 coronary heart disease patients with MDD, the use of ACEIs predicted a worse response to citalopram [204]. A possible caveat is that the use of ACEIs may cause bias towards more severe coronary disease, and thus a possible vascular, more refractory type of depression. Another interesting possibility, considering the antidepressant properties of ACEIs, is that their use may have prevented or even treated milder episodes of depression, creating a selection bias for more severe depression. Indeed, we know that an increasingly smaller percentage of patients respond or remit after trying a second or third drug after failing previous treatments [205], and that antidepressantnaïve patients improve their Hamilton Depression Rating Scale score more than those taking antidepressants in response to treatment [206]. The antidepressant effects of ACEIs can be further inferred both by mood effects in the population without a formal diagnosis of MDD, and in studies looking at quality of life. Mood elation was reported in healthy volunteers taking enalapril [207]. One RCT found a higher quality of life score was attained in patients taking captopril compared to other classes of antihypertensive drugs, despite similar blood pressure control [208]. A head-to-head comparison of captopril (a centrally acting ACEI) and enalapril (a non-centrally acting ACEI) reported no difference in antihypertensive efficacy, but that captopril had a superior effect on quality of life measurements [209]. In the Norwegian HUNT study [192], the depressive symptoms of a large population of 55,472 patients with systemic hypertension taking an ACEI were compared with those of patients with untreated systemic hypertension. Results showed an important trend in favour of the depressive symptom-reducing effects of ACEIs, as assessed by the Hospital Anxiety and Depression Rating Scale (OR 0.54, 95% CI 0.28– 1.08). Interestingly, those on BBs (OR 1.20, 95% CI 0.78–1.83) or on CCBs (OR 1.04, 95% CI 0.70–1.53) showed no reduction in depressive symptoms compared to the untreated systemic hypertension group. Again, this suggests that the pharmacological benefits of ACEIs and ARBs in depression are independent of their antihypertensive effects. A small open-label trial of 17 type 2 diabetic patients taking candesartan for at least 3 months found that depression scores were improved [210]. Nonetheless,thereareafewnegativereportsofthe effects of RAS drugs on mood. A small (n = 8), 6-week, double-blind crossover trial found captopril to have no positive effects on mood [211]. Another study found the BB atenolol superior to captopril for self-reported anxiety [212]. However, BBs are known to affect somatic anxiety, so measuring anxiety might not be an appropriate proxy for mood in this case. In a doubleblinded trial of 451 hypertensive patients taking either enalapril or the CCB amlodipine for 38 weeks, no differences were found between the two drugs in terms of qualityoflifemeasures[213].Another6-month double-blind trial with 540 hypertensive patients showed no superiority of cilazapril (an ACEI) over atenolol (a BB) [214]. Losartan was also not superior to nifedepine (a CCB) in a 12-week randomised doubleblind trial with 223 hypertensive patients [215]. Conclusions A growing body of evidence suggests a role for the angiotensin system in the pathophysiology of MDD. Drugs targeting the RAS reduce oxidative and inflammatory stress and enhance neurogenesis; all documented pathological markers in depression. Despite the heavy burden of depression, new drug development has been underwhelming. While RCTs providing definitive proof are yet to come, available preclinical and clinical data suggest the potential antidepressant properties of ACEIs and ARBs. The search for novel, effective, safe antiinflammatory drugs that act centrally in the brain are of fundamental interest. Future clinical trials targeting the brain angiotensin system are necessary to verify the usefulness of these agents in treating depression. Vian et al. BMC Medicine (2017) 15:144 Page 6 of 13 Table 1 Summary of clinical evidence Studies Findings Conclusion Limitations MDD Zubenko et al., 1984 Case report of mood-elevating effect of captopril in three MDD patients 3 patients: 72-year-old man with CHF 44-year-old woman with HT 67-year-old man with CHF Mood elevation of the 3 cases with captopril 3rd case developed psychotic symptoms Deicken, 1986 Case report of captopril treatment of MDD 52-year-old man with HT and D Improvement of MDD symptoms with captopril Germain & Chouinard, 1988 Case report of treatment of MDD with captopril 41-year-old man with D and posterior diagnosis of HT Total remission of the MDD episode with captopril Hertzman et al., 2005 Collection of case reports of lisinopril augmenting antidepressant response (9 MDD + 1 BD) Mood elevation of MDD and stabilised mood of the BD patient with lisonopril in patients already on antidepressants or MSs All patients being treated for HT Improved mood with a combination of antidepressants and lisinopril Rathmann et al., 1999 Case-control study of 972 diabetic patients OR for MDD: CCB: OR 2.2 (95% CI: 1.2–4.2) BB: OR 2.6 (95% CI: 1.1–7.0) ACEI: OR 1.3 (95% CI: 0.8–2.2) ACEI associated with reduced risk of MDD Screening for MDD made by general practitioners Williams et al., 2016 Case-control study of a 5-year cohort of 961 men with osteoporosis Exposure to ACEIs yields reduced risk of MDD (OR: 0.15, 95% CI: 0.04–0.51, P= 0.003) ACE inhibitors were associated with a reduced likelihood for MD onset Recall bias, unrecognised confounding and limited generalisability Boal et al., 2016 5-year cohort of 144,660 patients ACEI/ARB: 53% decreased risk of MD admissions CCB & BB: 2-fold increased risk of MD admissions TZ & NT did not attain statistical significance ACEI/ARB therapy had a neutral effect (or reduced risk) on MDs Results do not include milder levels of MDs treated in the community Negative findings in MDD Habra et al., 2010 RCT of citalopram in 284 patients with MDD and coronary disease Use of ACEIs associated with mean HAMD response of 1.36 versus 6.42 for non-ACEI use ACEI use predicted worse response to antidepressant Bias for more severe coronary disease Mood effects in non-depressed population Cohen et al., 1984 Case report of mood elation with enalapril Produced elation in normal volunteers (33% controls and 27% HT subjects) Mood elation effect Croog et al., 1986 RCT on the quality of life of captopril versus methyldopa versus propranolol in 626 male HT patients for 24 weeks Captopril: fewer side effects, and better scores for work performance, visual– motor functioning, and measures of life satisfaction versus methyldopa (P< 0.05 to < 0.01) Captopril: fewer side effects, less sexual dysfunction and greater improvement of measures of general well-being versus propranolol (P< 0.05 to < 0.01) Captopril group had better scores in tests of general well-being Testa et al., 1993 RCT on the quality of life of captopril versus enalapril in 379 HT men for 24 weeks Captopril: more favourable reports of overall quality of life, general perceived health, vitality, health status, sleep, emotional control (P< 0.05) The centrally acting ACEI (captopril) showed superior quality of life reports despite equal anti-HT response Johansen et al., 2012 HUNT study (Norway) 55,472 HT patients OR for depressive symptoms: ACEI: OR 0.54, 95% CI 0.28–1.08 BB: OR 1.20, 95% CI 0.78–1.83 CCBs: OR 1.04, 95% CI 0.70–1.53 Depressive symptoms were reduced in ACEI, compared to BB and CCB group Self-reported data Pavlatou et al., 2008 Open-label study of candesartan in 17 diabetic patients for ≥3 months Significant improvement in interpersonal sensitivity (P= 0.027) and depression scores (P= 0.026) Candesartan (an ARB) improves affect No control group Vian et al. BMC Medicine (2017) 15:144 Page 7 of 13 Acknowledgements Not applicable. Funding BSF is supported by a postdoctoral fellowship from Deakin University, Australia. CAK is supported by a postdoctoral scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; Brazil). AFC is supported by a research fellowship award from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Brazil). MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (grant number 1059660). The Department of Psychiatry and Behavioral Sciences of McGovern Medical School (USA) funds the Translational Psychiatry Program. The University of Texas Health Science Center at Houston (UTHealth). Laboratory of Neurosciences (Brazil) is a National Institute for Molecular Medicine centre, and a member of the Center of Excellence in Applied Neurosciences of Santa Catarina. Its research is supported by grants from CNPq (JQ), Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina (JQ); Instituto Cérebro e Mente (JQ) and Universidade do Extremo Sul Catarinense (JQ). JQ is a 1A CNPq Research Fellow. MB is supported by an NHMRC Senior Principal Research Fellowship (GNT1059660). Availability of data and materials Not applicable. Authors’contributions All authors participated in the design of this review. JV, CP, and VC performed the systematic review. JV, CP, VC, and BSF wrote the first draft of the manuscript. BSF and MB critically reviewed the first draft of the manuscript. All authors read and approved the final manuscript. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Author details 1 Psychiatry and Mental Health Department, Centro Hospitalar Lisboa Norte, Lisbon, Portugal. 2 Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. 3 Institut de Neuropsiquiatria i Adiccions (INAD), Parc de Salut Mar (PSM), Barcelona, Spain. 4 Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil. 5 Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK. 6 Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, UK. 7 Institute of clinical Research and Education in Medicine (IREM), Padova, Italy. 8 Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, UK. 9 Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. 10 Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. 11 Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. 12 Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil. 13 Deakin University, IMPACT Strategic Research Centre, School of Medicine, University Hospital Geelong, Barwon Health, Geelong, VIC, Australia. 14 Department of Psychiatry, Orygen the National Centre of Excellence for Youth Mental Health and Orygen Research Centre, and the Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia. 15 Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea. Received: 29 March 2017 Accepted: 18 July 2017 References 1. Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry. 2014;75:738–47. 2. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O’Neil A, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev. 2014;45:46–62. 3. Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry. 1999;45:1030–4. Table 1 Summary of clinical evidence (Continued) Negative findings in mood effects in non-depressed population Callender et al., 1983 Double-blind placebocontrolled crossover trial with captopril in 8 HT patients for 6 weeks Mood was slightly lower during captopril administration No evidence of mood effects of captopril during the trial Small sample and duration of study Deary et al., 1991 Double-blind crossover trial of atenolol and captopril in 18 HT patients for 12 weeks (6 weeks each drug) Patients reported feeling less anxious during treatment with atenolol (a BB) (P= 0.02). A BB was superior to an ACEI in self-reported anxiety BBs are known to have an effect in somatic anxiety Omvik et al., 1993 RCT on the quality of life of amlodipine versus enalapril in 461 HT patients for 50 weeks Indices on quality of life were unchanged or increased in both groups No difference between a CCB and an ACEI in quality of life Fletcher et al., 1992 RCT on the quality of life of cilazapril versus atenolol versus nifedipine in 540 HT patients for 6 months Little difference between quality of life measures in the cilazapril and atenolol groups. Both superior to nifedipine No significant differences in quality of life observed between an ACEI and a BB during the trial. Both were superior to a CCB. More nifedipine dropouts (17%) compared with atenolol (8%) and cilazapril (5%) Weir et al., 1996 RCT on the quality of life of losartan versus nifedipine in 223 HT patients for 12 weeks No significant differences in quality of life reports between groups No significant differences in quality of life were observed between an ACEI and a CCB Nifedipine had significantly more dropouts (12%) than losartan (5%) Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BB, beta-blockers; BD, bipolar disorder; CCB, calcium channel blockers; CHF, congestive heart failure; CI, confidence interval; D, depression; HAMD, Hamilton Rating Scale for Depression; HT, hypertensive; MDD, major depressive disordersl; MDs, mood disorders; MS, mood stabilisers; NT, non-treatment group; OR, odds ratio; RCT, randomised clinical trial; TZ, thiaziades Vian et al. BMC Medicine (2017) 15:144 Page 8 of 13 4. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002;438:1–14. 5. Gard PR. The brain renin-angiotensin system: a target for novel antidepressants and anxiolytics. Drug Dev Res. 2005;65:270–7. 6. Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ. Reninangiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1113–8. 7. Saavedra JM, Pavel J. Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRF-AVP axis and are potentially useful for the treatment of stress-related and mood disorders. Drug Dev Res. 2005;65:237–69. 8. Phillips MI, Schmidt-Ott KM. The discovery of renin 100 years ago. News Physiol Sci. 1999;14:271–4. 9. Ganten D, Boucher R, Genest J. Renin activity in brain tissue of puppies and adult dogs. Brain Res. 1971;33:557–9. 10. Ganten D, Marquez-Julio A, Granger P, Hayduk K, Karsunky KP, Boucher R, et al. Renin in dog brain. Am J Physiol. 1971;221:1733–7. 11. Bickerton RK, Buckley JP. Evidence for a central mechanism in angiotensin induced hypertension. Exp Biol Med. 1961;106:834–6. 12. Buggy J, Johnson AK. Angiotensin-induced thirst: effects of third ventricle obstruction and periventricular ablation. Brain Res. 1978;149:117–28. 13. Phillips MI, Felix D. Specific angiotensin II receptive neurons in the cat subfornical organ. Brain Res. 1976;109:531–40. 14. Johnson AK, Epstein AN. The cerebral ventricles as the avenue for the dipsogenic action of intracranial angiotensin. Brain Res. 1975;86:399–418. 15. Jones ES, Vinh A, McCarthy CA, Gaspari TA,WiddopRE.AT2receptors:functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316. 16. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210–26. 17. Santos RA, Silva AC S e, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor. Mas Proc Natl Acad Sci U S A. 2003;100:8258–63. 18. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417–27. 19. Harding JW, Cook VI, Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, et al. Identification of an AII(3–8) [AIV] binding site in guinea pig hippocampus. Brain Res. 1992;583:340–3. 20. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun. 1992;182:388–94. 21. Benicky J, Sánchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36:857–70. 22. Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. Psychoneuroendocrinology. 2011;36:1–18. 23. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem. 2009;109:656–69. 24. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis. 2008;31:58–73. 25. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, et al. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidasedependent two-wave cascade. J Neuroinflammation. 2011;8:129. 26. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson’s disease. Neurobiol Dis. 2013;58:209–19. 27. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain. 2012;135:3355–70. 28. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, LabandeiraGarcia JL. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging. 2012;33:e1–e11. 29. Borrajo A, Rodriguez-Perez AI, Diaz-Ruiz C, Guerra MJ, Labandeira-Garcia JL. Microglial TNF-αmediates enhancement of dopaminergic degeneration by brain angiotensin. Glia. 2014;62:145–57. 30. de Souza Gomes JA, de Souza GC, Berk M, Cavalcante LM, de Sousa FC, Budni J, et al. Antimanic-like activity of candesartan in mice: possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. Eur Neuropsychopharmacol. 2015;25:2086–97. 31. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, et al. Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett. 1991;129:318–20. 32. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 1989;170:607–12. 33. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208–10. 34. Aguilera G, Scott Young W, Kiss A, Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology. 1995;61:437–44. 35. Sumitomo T, Suda T, Nakano Y, Tozawa F, Yamada M, Demura H. Angiotensin II increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus. Endocrinology. 1991;128:2248–52. 36. Aguilera G, Kiss A, Luo X. Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol. 1995;7:775–83. 37. Wincewicz D, Juchniewicz A, Waszkiewicz N, Braszko JJ. Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. Pharmacol Biochem Behav. 2016;148:108–18. 38. Balla T, Baukal AJ, Eng S, Catt KJ. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol Pharmacol. 1991;40:401–6. 39. Geerling JC, Loewy AD. Aldosterone in the brain. Am J Physiol Ren Physiol. 2009;297:F559–76. 40. Murck H, Schüssler P, Steiger A. Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry. 2012;45:83–95. 41. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, GomezSanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997; 138:3369–73. 42. Wright JW, Harding JW. Brain renin-angiotensin - a new look at an old system. Prog Neurobiol. 2011;95:49–67. 43. de Kloet AD, Wang L, Ludin JA, Smith JA, Pioquinto DJ, Hiller H, et al. Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. Brain Struct Funct. 2016;221:891–912. 44. Yu L, Shao C, Gao L. Developmental expression patterns for angiotensin receptors in mouse skin and brain. J Renin Angiotensin Aldosterone Syst. 2014;15:139–49. 45. Mao C, Shi L, Xu F, Zhang L, Xu Z. Development of fetal brain reninangiotensin system and hypertension programmed in fetal origins. Prog Neurobiol. 2009;87:252–63. 46. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol. 1996;122:59–67. 47. Li JM, Mogi M, Tsukuda K, Tomochika H, Iwanami J, Min LJ, et al. Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptorinteracting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol. 2007;21:499–511. 48. Stroth U, Meffert S, Gallinat S, Unger T. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Mol Brain Res. 1998;53:187–95. 49. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol. 1999;13:1615–26. 50. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Man. 2011;7:749–59. 51. Alhusban A, Fouda AY, Bindu P, Ishrat T, Soliman S, Fagan SC. Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J Hypertens. 2015;33:170–80. 52. Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodríguez V, Desland F, et al. The angiotensin type 2 receptor agonist Compound 21 elicits Vian et al. BMC Medicine (2017) 15:144 Page 9 of 13